Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

1.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.7K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

931
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
931
Structure and Function of Platelets01:18

Structure and Function of Platelets

2.6K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Introduction to Hemostasis01:05

Introduction to Hemostasis

12.4K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
12.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic Risk Factors for Kidney Function in Individuals with Type 1 Diabetes.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Response to the Letter to the Editor Entitled "A Missing Genomic Dimension: The Small but Central Mitochondrial Genome in Diabetic Kidney Disease Genetics".

Kidney international reports·2026
Same author

Development of polyphenotypic scores to prioritize detection of G6PD rs1050828 carriers in African and African American populations.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Genetic Linkage for Bipolar Disorder to the Distal Region of Chromosome 19q: A Large Family Whole Genome Sequencing Study.

Bipolar disorders·2026
Same author

Investigator-Led Research to Improve the Diagnostic Assessment of Platelet Function Disorders: Reflections on the Challenges and Rewards.

International journal of laboratory hematology·2026
Same author

Insulin Response to Glucose and Type 2 Diabetes and Its Impact on Cardiometabolic Disease: A Sex-stratified Mendelian Randomization Study to Assess Potential Causality.

Canadian journal of diabetes·2026
Same journal

Von Willebrand disease: A century of progress.

Research and practice in thrombosis and haemostasis·2026
Same journal

Mechanism and kinetics study of MG1113, an anti-tissue factor pathway inhibitor antibody promoting hemostasis in hemophilia.

Research and practice in thrombosis and haemostasis·2026
Same journal

Resolving the dilution paradox to improve the interpretation of extracellular vesicle biomarker studies.

Research and practice in thrombosis and haemostasis·2026
Same journal

Heparin to prevent recurrent placenta-mediated pregnancy complications in women with antiphospholipid syndrome: a systematic review.

Research and practice in thrombosis and haemostasis·2026
Same journal

Thromboembolic ischemic stroke induces neutrophil recruitment and matrix metalloproteinase-9 release to enhance ischemic brain injury.

Research and practice in thrombosis and haemostasis·2026
Same journal

Real-world investigation of platelet apoptosis for mechanistic insights into severe immune thrombocytopenia and bleeding.

Research and practice in thrombosis and haemostasis·2026
See all related articles

Related Experiment Video

Updated: Dec 14, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.4K

Bleeding risks for uncharacterized platelet function disorders.

Justin Brunet1, Matthew Badin1, Michael Chong1

  • 1Department of Pathology and Molecular Medicine McMaster University Hamilton ON Canada.

Research and Practice in Thrombosis and Haemostasis
|July 21, 2020
PubMed
Summary
This summary is machine-generated.

Individuals with platelet function disorders (PFDs) causing impaired aggregation or dense granule deficiency (DGD) face significantly higher bleeding risks. These risks include mucocutaneous bleeding and complications after medical challenges.

Keywords:
blood platelet disordershemorrhagehemostasisodds ratioplatelet storage pool deficiencywound healing

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

930
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.2K

Related Experiment Videos

Last Updated: Dec 14, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.4K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

930
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.2K

Area of Science:

  • Hematology
  • Genetics
  • Clinical Medicine

Background:

  • Nonsyndromic platelet function disorders (PFDs) impacting aggregation or causing dense granule deficiency (DGD) have uncertain bleeding risks.
  • Quantifying these risks is crucial for patient management and understanding disease pathology.

Purpose of the Study:

  • To quantify the bleeding risks associated with uncharacterized PFDs in a cohort of consecutive cases.
  • To explore the relationship between specific PFD characteristics and bleeding symptoms.

Main Methods:

  • Recruited consecutive cases with uncharacterized PFDs (reduced maximal aggregation and/or nonsyndromic DGD) and family members.
  • Utilized exome sequencing to identify genetic variants, focusing on RUNX1.
  • Assessed bleeding using standardized tools to calculate bleeding scores and odds ratios (ORs) against controls.

Main Results:

  • Participants with PFD exhibited significantly increased bleeding scores compared to controls.
  • Elevated risks were observed for mucocutaneous bleeding (OR, 4-207), challenge-related bleeding (OR, 12-43), and transfusion requirements (OR, 100).
  • Reduced maximal aggregation with collagen correlated with wound healing issues, while severe DGD was linked to surgical bleeding (P < .04).

Conclusions:

  • PFDs characterized by impaired maximal aggregation and/or nonsyndromic DGD are associated with substantially increased bleeding risks.
  • Specific bleeding manifestations correlate with the severity of DGD and impaired collagen aggregation responses.